Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 2
2010 7
2011 10
2012 2
2013 7
2014 6
2015 13
2016 8
2017 2
2018 4
2019 8
2020 6
2021 3
2022 5
2023 3
2024 5
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Rare molecular subtypes of lung cancer.
Harada G, Yang SR, Cocco E, Drilon A. Harada G, et al. Among authors: cocco e. Nat Rev Clin Oncol. 2023 Apr;20(4):229-249. doi: 10.1038/s41571-023-00733-6. Epub 2023 Feb 20. Nat Rev Clin Oncol. 2023. PMID: 36806787 Free PMC article. Review.
ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer.
Xu G, Chhangawala S, Cocco E, Razavi P, Cai Y, Otto JE, Ferrando L, Selenica P, Ladewig E, Chan C, Da Cruz Paula A, Witkin M, Cheng Y, Park J, Serna-Tamayo C, Zhao H, Wu F, Sallaku M, Qu X, Zhao A, Collings CK, D'Avino AR, Jhaveri K, Koche R, Levine RL, Reis-Filho JS, Kadoch C, Scaltriti M, Leslie CS, Baselga J, Toska E. Xu G, et al. Among authors: cocco e. Nat Genet. 2020 Feb;52(2):198-207. doi: 10.1038/s41588-019-0554-0. Epub 2020 Jan 13. Nat Genet. 2020. PMID: 31932695 Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, Shifman S, Tu HY, Myers ML, Xu C, Mattar M, Khodos I, Little M, Qeriqi B, Weitsman G, Wilhem CJ, Lalani AS, Diala I, Freedman RA, Lin NU, Solit DB, Berger MF, Barber PR, Ng T, Offin M, Isbell JM, Jones DR, Yu HA, Thyparambil S, Liao WL, Bhalkikar A, Cecchi F, Hyman DM, Lewis JS, Buonocore DJ, Ho AL, Makker V, Reis-Filho JS, Razavi P, Arcila ME, Kris MG, Poirier JT, Shen R, Tsurutani J, Ulaner GA, de Stanchina E, Rosen N, Rudin CM, Scaltriti M. Li BT, et al. Among authors: cocco e. Cancer Discov. 2020 May;10(5):674-687. doi: 10.1158/2159-8290.CD-20-0215. Epub 2020 Mar 25. Cancer Discov. 2020. PMID: 32213539 Free PMC article.
Inhibition of NR2F2 restores hormone therapy response to endocrine refractory breast cancers.
Cai Y, Zhao P, Wu F, Zhao H, Shao H, Marra A, Patel P, O'Connell E, Fink E, Miele MM, Li Z, De Stanchina E, Cocco E, Razavi P, Toska E, Fanning SW, Xu G, Sablina AA, Scaltriti M, Chandarlapaty S. Cai Y, et al. Among authors: cocco e. Sci Transl Med. 2025 Jun 4;17(801):eadk7786. doi: 10.1126/scitranslmed.adk7786. Epub 2025 Jun 4. Sci Transl Med. 2025. PMID: 40465692 Free PMC article.
José Baselga (1959-2021).
Castel P, Toska E, Vasan N, Cocco E, Scaltriti M. Castel P, et al. Among authors: cocco e. Cancer Cell. 2021 May 10;39(5):581-582. doi: 10.1016/j.ccell.2021.04.003. Epub 2021 Apr 29. Cancer Cell. 2021. PMID: 33930314 Free article. No abstract available.
Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
Blawski R, Vokshi BH, Guo X, Kittane S, Sallaku M, Chen W, Gjyzari M, Cheung T, Zhang Y, Simpkins C, Zhou W, Kulick A, Zhao P, Wei M, Shivashankar P, Prioleau T, Razavi P, Koche R, Rebecca VW, de Stanchina E, Castel P, Chan HM, Scaltriti M, Cocco E, Ji H, Luo M, Toska E. Blawski R, et al. Among authors: cocco e. Cell Rep. 2024 May 28;43(5):114174. doi: 10.1016/j.celrep.2024.114174. Epub 2024 May 2. Cell Rep. 2024. PMID: 38700982 Free PMC article.
Responsiveness of different MET tumour alterations to type I and type II MET inhibitors.
Murciano-Goroff YR, Foglizzo V, Chang J, Rekhtman N, Sisk AE, Gibson J, Judka L, Clemens K, Roa P, Ahmed SS, Bremer NV, Binaco CL, Muzungu SK, Rodriguez E, Merrill M, Sgroe E, Repetto M, Stadler ZK, Berger MF, Yu HA, Toska E, Kannan S, Verma CS, Drilon A, Cocco E. Murciano-Goroff YR, et al. Among authors: cocco e. Clin Transl Med. 2025 May;15(5):e70338. doi: 10.1002/ctm2.70338. Clin Transl Med. 2025. PMID: 40437874 Free PMC article.
Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents.
Roa P, Foglizzo V, Harada G, Repetto M, Kulick A, de Stanchina E, de Marchena M, Auwardt S, Sayed Ahmed S, Bremer NV, Yang SR, Feng Y, Zhou C, Kong N, Liang R, Xu H, Zhang B, Bardelli A, Toska E, Ventura A, Drilon A, Cocco E. Roa P, et al. Among authors: cocco e. Br J Cancer. 2024 Aug;131(3):601-610. doi: 10.1038/s41416-024-02760-1. Epub 2024 Jun 20. Br J Cancer. 2024. PMID: 38902532 Free PMC article.
89 results